Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

Drugs targeting the glucagon-like peptide 1 receptor (GLP-1R) offer several positive effects for individuals with type 2 diabetes, including the lowering of blood glucose and the reduction of body ...

New multi-omic data reveal that GLP-1 signaling in the brain can drive body-wide rejuvenation, offering a potential weight-neutral path to preserving strength and organ resilience with age. Study: ...

New evidence shows that GLP-1–based therapies not only lower glucose levels and aid in weight loss but also reduce inflammation in the heart, kidneys, liver, and brain, revealing a broader therapeutic ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...